Marzeptacog alfa

Drug Profile

Marzeptacog alfa

Alternative Names: CB 813; CB 813d; Marzeptacog alpha; PF-05280602; PF-5280602; Recombinant Factor VIIa variant (813d) - Pfizer

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Catalyst Biosciences
  • Class Blood coagulation factors; Peptide hydrolases; Recombinant proteins
  • Mechanism of Action Factor VIIa stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haemophilia; Surgical blood loss

Most Recent Events

  • 19 Dec 2016 Preclinical trials in Haemophilia in USA (SC)
  • 04 Nov 2016 Catalyst Biosciences plans a clinical trial for Haemophilia in USA
  • 20 Jun 2016 Catalyst Biosciences has patent protection for CB 813d in European union and Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top